|
Joseph Turner joins Kythera’s Board with more than 25 years of financial management experience in pharmaceutical and biotech industries worldwide. As Chief Financial Officer of several early stage industrial companies, Turner was responsible for eight equity offerings, including three Initial Public Offerings (IPOs), raising a total of $450 million in the public and private markets. He spent seven years as Chief Financial Officer at Myogen, Inc. where he led two private and three public rounds of financing and was a key player in the negotiation of the $2.5 billion sale of the company to Gilead Sciences in 2006. Prior to Myogen, Turner was Vice President of Finance at Cortech, Inc. where he led the transition from a private concern to a public company and successfully completed both IPO and follow-on offerings. Other financial leadership roles include Director of Finance, Eli Lilly and Company (Switzerland); Treasurer, Eli Lilly and Company (Switzerland); and Vice President of Finance, Centaur Pharmaceuticals. He is member of the Board of Directors of Sequel Pharmaceuticals and of SGX Pharmaceuticals and is a former board member and Chairman of the Audit Committee of NovaCardia, Inc. Turner holds a BA in Chemistry from Swarthmore College; an MA in Molecular Biology from the University of Colorado at Boulder; and an MBA from University of North Carolina at Chapel Hill. | 